Masimo Co. (NASDAQ:MASI) Holdings Lifted by Fmr LLC

FMR LLC lifted its stake in shares of Masimo Co. (NASDAQ:MASI - Free Report) by 41.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,756,618 shares of the medical equipment provider's stock after buying an additional 1,970,883 shares during the quarter. FMR LLC owned approximately 12.62% of Masimo worth $900,860,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also made changes to their positions in the stock. Farallon Capital Management LLC boosted its holdings in Masimo by 13.6% in the first quarter. Farallon Capital Management LLC now owns 1,489,563 shares of the medical equipment provider's stock worth $218,742,000 after purchasing an additional 177,914 shares during the period. Westfield Capital Management Co. LP boosted its position in shares of Masimo by 23.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock worth $185,869,000 after buying an additional 262,370 shares during the period. Thrivent Financial for Lutherans grew its holdings in Masimo by 42.1% in the 2nd quarter. Thrivent Financial for Lutherans now owns 1,217,357 shares of the medical equipment provider's stock worth $153,314,000 after buying an additional 360,497 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Masimo by 9.8% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider's stock valued at $105,619,000 after acquiring an additional 70,440 shares during the period. Finally, Point72 Asset Management L.P. raised its stake in Masimo by 107.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 677,677 shares of the medical equipment provider's stock valued at $85,347,000 after acquiring an additional 351,523 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on MASI shares. Raymond James raised Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price target for the company in a research note on Wednesday, November 6th. Wells Fargo & Company raised their target price on shares of Masimo from $160.00 to $171.00 and gave the company an "overweight" rating in a research note on Wednesday, November 6th. Stifel Nicolaus restated a "buy" rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. BTIG Research increased their price objective on shares of Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a report on Monday, October 14th. Finally, Piper Sandler raised their price objective on shares of Masimo from $165.00 to $180.00 and gave the company an "overweight" rating in a research note on Wednesday, November 6th. Three analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $167.00.

Masimo Price Performance

NASDAQ MASI traded down $1.37 on Thursday, reaching $170.89. The company's stock had a trading volume of 534,498 shares, compared to its average volume of 677,370. The firm's 50 day moving average is $148.22 and its two-hundred day moving average is $129.32. The stock has a market cap of $9.15 billion, a PE ratio of 117.86 and a beta of 0.97. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. Masimo Co. has a twelve month low of $91.60 and a twelve month high of $178.27.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, beating the consensus estimate of $0.84 by $0.14. The business had revenue of $504.60 million during the quarter, compared to analyst estimates of $502.87 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business's quarterly revenue was up 5.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.63 earnings per share. As a group, sell-side analysts predict that Masimo Co. will post 4.04 EPS for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.